An immunoconjugate comprising a humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof that specifically binds to human ADAM9 and cyno ADAM9: (I) wherein said humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof is conjugated to a pharmacological agent; and (II) wherein said humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof comprises a Light Chain Variable (VL) Domain and a Heavy Chain Variable (VH) Domain, wherein said Heavy Chain Variable Domain comprises a CDR H 1 Domain, a CDR H 2 Domain and a CDR H 3 Domain, and said Light Chain Variable Domain comprises a CDR L 1 Domain, a CDR L 2 Domain, and a CDR L 3 Domain, wherein: (A) said CDR H 1 Domain comprises the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:34; and (B) said CDR H 2 Domain comprises the amino acid sequence of SEQ ID NO: 9, SEQ ID NO:35 or SEQ ID NO:36; and (C) said CDR H 3 Domain comprises amino acid sequence of any one of SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45 or SEQ ID NO:46; and wherein: (A) said CDR L 1 Domain has the amino acid sequence of SEQ ID NO:12, SEQ ID NO:62, SEQ ID NO:63, or SEQ ID NO:64; and (B) said CDR L 2 Domain has the amino acid sequence of SEQ ID NO:13; and (C) said CDR L 3 Domain has the amino acid sequence of SEQ ID NO:14 or SEQ ID NO:65. (I) wherein said humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof is conjugated to a pharmacological agent; and (II) wherein said humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof comprises a Light Chain Variable (VL) Domain and a Heavy Chain Variable (VH) Domain, wherein said Heavy Chain Variable Domain comprises a CDR H 1 Domain, a CDR H 2 Domain and a CDR H 3 Domain, and said Light Chain Variable Domain comprises a CDR L 1 Domain, a CDR L 2 Domain, and a CDR L 3 Domain, wherein: (A) said CDR H 1 Domain comprises the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:34; and (B) said CDR H 2 Domain comprises the amino acid sequence of SEQ ID NO: 9, SEQ ID NO:35 or SEQ ID NO:36; and (C) said CDR H 3 Domain comprises amino acid sequence of any one of SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45 or SEQ ID NO:46; and wherein: (A) said CDR L 1 Domain has the amino acid sequence of SEQ ID NO:12, SEQ ID NO:62, SEQ ID NO:63, or SEQ ID NO:64; and (B) said CDR L 2 Domain has the amino acid sequence of SEQ ID NO:13; and (C) said CDR L 3 Domain has the amino acid sequence of SEQ ID NO:14 or SEQ ID NO:65. (A) said CDR H 1 Domain comprises the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:34; and (B) said CDR H 2 Domain comprises the amino acid sequence of SEQ ID NO: 9, SEQ ID NO:35 or SEQ ID NO:36; and (C) said CDR H 3 Domain comprises amino acid sequence of any one of SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45 or SEQ ID NO:46; and (A) said CDR L 1 Domain has the amino acid sequence of SEQ ID NO:12, SEQ ID NO:62, SEQ ID NO:63, or SEQ ID NO:64; and (B) said CDR L 2 Domain has the amino acid sequence of SEQ ID NO:13; and (C) said CDR L 3 Domain has the amino acid sequence of SEQ ID NO:14 or SEQ ID NO:65. <EOS>